Abstract

Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disorder characterized by the selective degeneration of defined subgroups of motoneuron in the brainstem, spinal cord and motor cortex with signature hallmarks of mitochondrial Ca2+ overload, free radical damage, excitotoxicity and impaired axonal transport. Although intracellular disruptions of cytosolic and mitochondrial calcium, and in particular low cytosolic calcium ([Ca2+]c) buffering and a strong interaction between metabolic mechanisms and [Ca2+]i have been identified predominantly in motoneuron impairment, the causes of these disruptions are unknown. The existing evidence suggests that the mutant superoxide dismutase1 (mtSOD1)-mediated toxicity in ALS acts through mitochondria, and that alteration in cytosolic and mitochondria-ER microdomain calcium accumulation are critical to the neurodegenerative process. Furthermore, chronic excitotoxcity mediated by Ca2+-permeable AMPA and NMDA receptors seems to initiate vicious cycle of intracellular calcium dysregulation which leads to toxic Ca2+ overload and thereby selective neurodegeneration. Recent advancement in the experimental analysis of calcium signals with high spatiotemporal precision has allowed investigations of calcium regulation in-vivo and in-vitro in different cell types, in particular selectively vulnerable/resistant cell types in different animal models of this motoneuron disease. This review provides an overview of latest advances in this field, and focuses on details of what has been learned about disrupted Ca2+ homeostasis and mitochondrial degeneration. It further emphasizes the critical role of mitochondria in preventing apoptosis by acting as a Ca2+ buffers, especially in motoneurons, in pathophysiological conditions such as ALS.

Highlights

  • Amyotrophic lateral sclerosis (ALS) is an incurable, adultonset, deadly neurodegenerative disorder distinguished by the progressive degeneration of a defined motoneuron (MN) population in the brain stem, spinal cord and motor cortex

  • This hypothesis is further strengthened by the appearance of abnormalities in mitochondrial ultrastructure and vacuoles formation resulted from degenerating mitochondria found in post mortem samples of ALS [28,29,30,31]

  • In spite of rigourous research for years there are several important questions still unanswered; these include: (a) does the expression of mutant superoxide dismutase1 (mtSOD1) at physiological levels causes morphological and structural abnormalities of mitochondrial assembly and its calcium buffering capacity? (b) At pathophysiological levels, does the mitochondria-endoplasmic reticulum (ER) and EMRCC Ca2+ sequestration source specificity and spatiotemporal properties of [Ca2+]i signaling varies at sub cellular level in and around microdomain? (c) In the presence of mtSOD1 gene, what are the consequences of alterations in mitochondrial function on Ca2+ homeostasis and ER-mitochondria calcium cycle (ERMCC)? Numerous developments and improvements in visualization of diseased MNs and spatiotemporal resolution of mitochondria-ER calcium signaling cascades have the potential to bring novel insights

Read more

Summary

Introduction

Amyotrophic lateral sclerosis (ALS) is an incurable, adultonset, deadly neurodegenerative disorder distinguished by the progressive degeneration of a defined motoneuron (MN) population in the brain stem, spinal cord and motor cortex. Mitochondrial dysfunction, Ca2+ homeostasis and ALS: a multifactorial disease mechanism The Ca2+-dependent signaling mechanisms that result in the enhanced vulnerability of MNs in ALS disease and associated mouse models are critical for normal cellular function. Increased Ca2+ uptake by mitochondria leads to up-regulation of the enzymes activity in oxidative metabolism, resulting in cell-specific metabolic changes [149,150,151] This hypothesis is further strengthened by the appearance of abnormalities in mitochondrial ultrastructure and vacuoles formation resulted from degenerating mitochondria found in post mortem samples of ALS [28,29,30,31]. The lessons learned from a decade of research using the mtSOD1 animal model might help scientists in finding cures for neurodegeneration where single-drug treatments have confirmed insufficient for effective treatment of ALS

Conclusions
36. Jaiswal MK
38. Beal MF
63. Neher E
69. Cleveland DW: From charcot to SOD1
74. Strong MJ
Findings
79. Beal MF
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call